PEG-30二聚羟基硬脂酸酯 | 827596-80-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: PEG-30二聚羟基硬脂酸酯
• 英文名称: 12-Hydroxyoctadecanoic acid--oxirane (1/1)
• 英文别名: 12-hydroxyoctadecanoic acid;oxirane
• CAS: 827596-80-5
• 化学式: C20H40O4
• 分子量: 344.5
• InChiKey: WOGBVVJPYOUGFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.32
• 重原子数：
  24
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• STERILE INJECTABLE COMPOSITION COMPRISING CARFILZOMIB
  申请人：Cadila Healthcare Limited

  公开号：EP3536309A1

  公开（公告）日：2019-09-11

  The present invention relates to sterile injectable compositions comprising carfilzomib and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.

  本发明涉及包含卡非佐米和一种或多种磷脂的无菌注射剂组合物。本发明还涉及制备无菌注射用组合物的工艺。
• Stabilized liquid fosaprepitant formulations
  申请人：Cipla Limited

  公开号：US10307432B2

  公开（公告）日：2019-06-04

  The present invention relates to stable pharmaceutical compositions of fosaprepitant or a salt thereof in the form of ready-to-use or ready-to-dilute compositions suitable for parenteral administration.

  本发明涉及福沙匹坦或其盐的稳定药物组合物，其形式为适合肠外给药的即用型或即稀释型组合物。
• Storage stable aqueous injectable solution comprising diclofenac
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US11110073B2

  公开（公告）日：2021-09-07

  The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.

  本发明涉及一种由双氯芬酸和聚乙烯吡咯烷酮组成的稳定的可注射水溶液。本发明还涉及制备注射溶液的工艺。
• Storage-stable ready-to-use injectable formulations of thiotepa
  申请人：RK Pharma Solutions LLC

  公开号：US11260065B2

  公开（公告）日：2022-03-01

  A stable, ready-to-use injectable solution including thiotepa and one or more pharmaceutically acceptable solvents, co-solvents, and/or solubilizing agents. Formulations retain at least 90% and as high as 99% of the purity of thiotepa as measured by HPLC after storage at 25° C./60% RH for a period of 7 days. Certain formulations retain at least 99% of the purity of thiotepa as measured by HPLC after storage for at least six months at 2-8° C.

  一种稳定的即用型注射溶液，包括噻替帕和一种或多种药学上可接受的溶剂、助溶剂和/或增溶剂。在 25°C /60% 相对湿度条件下储存 7 天后，经 HPLC 测定，制剂可保留至少 90% 或高达 99% 的噻替帕纯度。某些制剂在 2-8°C、60%相对湿度条件下储存至少 6 个月后，经 HPLC 测定，噻替派的纯度至少可保持 99%。
• PHARMACEUTICAL COMPOSITION
  申请人：Cipla Limited

  公开号：EP2846769A1

  公开（公告）日：2015-03-18